The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Translational genomics and recent advances in oral squamous cell carcinoma
Open accessAbstract
Oral squamous cell carcinomas (OSCC) are a heterogeneous group of cancers arising from the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle risk habits including smoking, excessive alcohol consumption and betel quid chewing. Cetuximab, targeting the epidermal growth factor receptor was approved for the treatment of OSCC in 2006, and remains the only molecular targeted therapy available for OSCC. Here, we reviewed the current findings from genomic analyses of OSCC and discuss how these studies inform on the biological mechanisms underlying OSCC. Exome sequencing revealed that the significantly mutated genes are mainly tumour suppressors. Mutations in FAT1, CASP8, CDKN2A, and NOTCH1 are more frequently found in OSCC when compared to non-OSCC head and neck cancers and other squamous cell carcinomas, and HRAS and PIK3CA are the only significantly mutated oncogenes. The distribution of these mutations also differs in populations with distinct risk habits. Gene expression-based molecular classification showed that OSCC can be divided into distinct subtypes and these have a preferential response to different types of therapies, suggesting that these classifications could have clinical implications. More recently, with the approval of checkpoint inhibitors for the treatment of cancers including OSCC, genomics studies also dissected the genetic signatures of the immune compartment to delineate immune-active and -exhausted subtypes that could inform on the immune status of OSCC patients and guide the development of novel therapies to improve response to immunotherapy. Taken together, genomics studies are informing on the biology of both the epithelial and stromal compartments underlying OSCC development, and we discuss the opportunities and challenges in using these to derive clinical benefit for OSCC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H., & Gillison, M. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065497 · Cited by 2,692
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70311-0 · Cited by 1,978
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T.-X., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Herrero, R. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg107 · Cited by 1,228
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Geeleher, P., Cox, N. J., & Huang, R. S. (2014) · Genome Biology · doi:10.1186/gb-2014-15-3-r47 · Cited by 890
Grandis, J. R., & Tweardy, D. J. (1993) · PubMed · Cited by 851
The head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 765
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
Chung, C. H., Parker, J. S., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., Butterfoss, D., Xiang, D., Zanation, A., Yin, X., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00112-6 · Cited by 678
Bauml, J., Seiwert, T. Y., Pfister, D. G., Worden, F., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L., Sukari, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 663
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0026 · Cited by 614
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Pickering, C. R., Zhang, J., Yoo, S. Y., Bengtsson, L., Moorthy, S., Neskey, D. M., Zhao, M., Ortega Alves, M. V., Chang, K., Drummond, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0537 · Cited by 559
Comprehensive analysis of the clinical immuno-oncology landscape
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx755 · Cited by 508
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Hsu, C., Lee, S.-H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J. M., Algazi, A., van Brummelen, E. M. J., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3675 · Cited by 464
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Cowley, G. S., Weir, B. A., Vazquez, F., Tamayo, P., Scott, J. A., Rusin, S., East-Seletsky, A., Ali, L. D., Gerath, W. F., Pantel, S. E., et al. (2014) · Scientific Data · doi:10.1038/sdata.2014.35 · Cited by 387
Keck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
Morris, L. G. T., Kaufman, A. M., Gong, Y., Ramaswami, D., Walsh, L. A., Turcan, Ş., Eng, S., Kannan, K., Zou, Y., Peng, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2538 · Cited by 366
India Project Team of the International Cancer Genome Consortium, Maitra, A., Biswas, N. K., Amin, K., Kowtal, P., Kumar, S., Das, S., Sarin, R., Majumder, P. P., Bagchi, I., et al. (2013) · Nature Communications · doi:10.1038/ncomms3873 · Cited by 355
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 343
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Campbell, J. D., Yau, C., Bowlby, R., Liu, Y., Brennan, K., Fan, H., Taylor, A. M., Wang, C., Walter, V., Akbani, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.063 · Cited by 342
Walter, V., Yin, X., Wilkerson, M. D., Cabanski, C. R., Zhao, N., Du, Y., Ang, M. K., Hayward, M. C., Salazar, A. H., Hoadley, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056823 · Cited by 327
Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L. K., Le, Q.-T., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 275
Guha, N., Warnakulasuriya, S., Vlaanderen, J., & Straif, K. (2014) · International Journal of Cancer · doi:10.1002/ijc.28643 · Cited by 267
Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas
Rosario, S. R., Long, M. D., Affronti, H. C., Rowsam, A. M., Eng, K. H., & Smiraglia, D. J. (2018) · Nature Communications · doi:10.1038/s41467-018-07232-8 · Cited by 266
Epstein-Barr virus and nasopharyngeal carcinoma
Young, L. S., & Dawson, C. W. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.014.10197 · Cited by 253
Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories
The GEUVADIS Consortium, 't Hoen, P. A. C., Friedländer, M. R., Almlöf, J., Sammeth, M., Pulyakhina, I., Anvar, S. Y., Laros, J. F. J., Buermans, H. P. J., Karlberg, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2702 · Cited by 250
Partlová, S., Bouček, J., Kloudová, K., Lukešová, E., Zábrodský, M., Grega, M., Fučíková, J., Truxová, I., Tachezy, R., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.4161/21624011.2014.965570 · Cited by 241
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Li, B., Cui, Y., Nambiar, D. K., Sunwoo, J. B., & Li, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4085 · Cited by 197
Assembly and activation of the Hippo signalome by FAT1 tumor suppressor
Martin, D., Degese, M. S., Vitale-Cross, L., Iglesias-Bartolome, R., Valera, J. L. C., Wang, Z., Feng, X., Yeerna, H., Vadmal, V., Moroishi, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04590-1 · Cited by 174
Self-citationYoshitake, Y., Fukuma, D., Yuno, A., Hirayama, M., Nakayama, H., Tanaka, T., Nagata, M., Takamune, Y., Kawahara, K., Nakagawa, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0202 · Cited by 162
Pickering, C. R., Zhang, J., Neskey, D. M., Zhao, M., Jasser, S. A., Wang, J., Ward, A. M., Tsai, C. J., Alves, M. V. O., Zhou, J. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0565 · Cited by 155
Epstein–Barr Virus and Nasopharyngeal Carcinoma
Zhou, X., Xiao, X., Chen, F., Huang, T., & Zhang, Z. (2014) · Wiley eBooks · doi:10.1002/9781118826621.ch14 · Cited by 142
Cecco, L. D., Nicolau, M., Giannoccaro, M., Daidone, M. G., Bossi, P., Locati, L. D., Licitra, L. F., & Canevari, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3301 · Cited by 139
Su, S., Lin, C., Liu, Y., Fan, W., Chen, M., Yu, C.-P., Yang, W., Su, C., Chuang, C., Li, W., et al. (2017) · Theranostics · doi:10.7150/thno.18551 · Cited by 136
Calabrò, A., Beißbarth, T., Kuner, R., Stojanov, M., Benner, A., Asslaber, M., Ploner, F., Zatloukal, K., Samonigg, H., Poustka, A., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0105-3 · Cited by 124
Aggarwal, C., Cohen, R., Morrow, M., Kraynyak, K., Sylvester, A., Knoblock, D., Bauml, J., Weinstein, G., Lin, A., Boyer, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 124
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 120
Common and Complex Notch1 Mutations in Chinese Oral Squamous Cell Carcinoma
Song, X., Xia, R., Li, J., Long, Z., Ren, H., Chen, W., & Mao, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1050 · Cited by 109
Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis
Farhood, Z., Simpson, M. C., Ward, G. M., Walker, R. J., & Osazuwa‐Peters, N. (2018) · The Laryngoscope · doi:10.1002/lary.27490 · Cited by 107
Notch1 Mutations Are Drivers of Oral Tumorigenesis
Izumchenko, E., Sun, K., Jones, S., Brait, M., Agrawal, N., Koch, W. M., McCord, C. L., Riley, D. R. J., Angiuoli, S. V., Velculescu, V. E., et al. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0257 · Cited by 98
Vettore, A. L., Ramnarayanan, K., Poore, G. D., Lim, K. J., Ong, C. K., Huang, K. K., Leong, H. S., Chong, F. T., Lim, T. K., Lim, W. K., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0219-2 · Cited by 97
Self-citationPhase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., Pond, G. R., Johnson, C., Colevas, A. D., Synold, T. W., et al. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9098-8 · Cited by 88
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma
Cai, Y., Dodhia, S., & Su, G. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14729 · Cited by 88
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
Jung, K., Kang, H., & Mehra, R. (2018) · Cancers of the Head & Neck · doi:10.1186/s41199-018-0030-z · Cited by 82
Kemp, S. R. M., Nagel, R., van Walsum, M., van der Meulen, I. H., van Beusechem, V. W., Braakhuis, B. J. M., & Brakenhoff, R. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2539 · Cited by 75
Miyazaki, T. (2011) · Oncology Reports · doi:10.3892/or.2011.1324 · Cited by 73
The opposing roles of NOTCH signalling in head and neck cancer: a mini review
Yap, L. F., Lee, D., Khairuddin, A. N. M., Pairan, M., Puspita, B., Siar, C. H., & Paterson, I. C. (2015) · Oral Diseases · doi:10.1111/odi.12309 · Cited by 72
Approaches to target tractability assessment – a practical perspective
Brown, K. K., Hann, M. M., Lakdawala, A. S., Santos, R., Thomas, P. J., & Todd, K. (2018) · MedChemComm · doi:10.1039/c7md00633k · Cited by 69
DeSigN: connecting gene expression with therapeutics for drug repurposing and development
Lee, B. K. B., Tiong, K. H., Chang, J. K., Liew, C. S., Rahman, Z. A. A., Tan, A. C., Khang, T. F., & Cheong, S. C. (2017) · BMC Genomics · doi:10.1186/s12864-016-3260-7 · Cited by 66
Self-citationDoes Notch play a tumor suppressor role across diverse squamous cell carcinomas?
Zhang, M., Biswas, S., Qin, X., Gong, W., Deng, W., & Yu, H. (2016) · Cancer Medicine · doi:10.1002/cam4.731 · Cited by 60
Rodon, J. A., Fidalgo, J. A. P., Krop, I. E., Burris, H. A., Zotano, Á. G., Britten, C. D., Becerra, C., Schellens, J. H. M., Richards, D., Schüler, M., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3610-z · Cited by 53
Common Oncogenic Mutations Are Infrequent in Oral Squamous Cell Carcinoma of Asian Origin
Zanaruddin, S. N. S., Yee, P. S., Hor, S. Y., Kong, Y. H., Ghani, W. M. N., Mustafa, W. M. W., Zain, R. B., Prime, S. S., Rahman, Z. A. A., & Cheong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080229 · Cited by 49
Self-citationIn vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam, B., Kim, S., Ahn, Y., Kim, T. M., Lee, S., Kim, D., & Heo, D. S. (2015) · PubMed · Cited by 48
Al-Hebshi, N. N., Li, S., Nasher, A. T., El‐Setouhy, M., Al-Sanosi, R. M., Blancato, J. K., & Loffredo, C. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30068 · Cited by 48
Nur, S. Z., Bernard, K. B. L., Zheng, W. W., Iuan, S. C., Pei, S. Y., Gan, C. P., Kein, S. M., Zainal, A. A. R., Gutkind, J. S., Vyomesh, P., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0257 · Cited by 40
Kemp, S. R. M., Brink, A., van der Meulen, I. H., de Menezes, R. X., Beest, D. E. T., Leemans, C. R., van Beusechem, V. W., Braakhuis, B. J. M., & Brakenhoff, R. H. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0457 · Cited by 36
FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma
(2019) · Case Medical Research · doi:10.31525/cmr-14e3317 · Cited by 23
Yee, P. S., Zainal, N. S., Gan, C. P., Lee, B. K. B., Mun, K. S., Abraham, M. T., Ismail, S. M., Rahman, Z. A. A., Patel, V., & Cheong, S. C. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00626-8 · Cited by 19
Self-citation
Cited by
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Metadata
- Authors
- Chai, A. W. Y., Lim, K. P., & Cheong, S. C.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 61
- Pages
- 71-83
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2973887189
- Cited by
- 298
- References
- 88
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.